Trial Profile

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Anastrozole (Primary) ; Camizestrant (Primary) ; Capivasertib (Primary) ; Everolimus (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary)
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions; First in man
Acronyms SERENA-1
Sponsors AstraZeneca

Most Recent Events

02 Apr 2025 Planned End Date changed from 4 Jul 2025 to 28 Nov 2025.
24 Dec 2024 Planned End Date changed from 16 Sep 2024 to 4 Jul 2025.
13 Aug 2024 Planned primary completion date changed from 8 Jul 2024 to 16 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com